What one share of Akebia Therapeutics holds
We are a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease.
Akebia Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.83 |
|---|---|
| Profit | −$0.11 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | $0.15 |
| Cash and investments | $0.57 |
| Debt | $0.18 |
| Book value | $0.09 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | — | −$27.82 | — | — | — | −$143.90 |
| 2013 | — | −$126.94 | $0.03 | −$20.87 | — | — |
| 2014 | — | −$8.04 | $0.01 | −$1.80 | — | $5.11 |
| 2015 | — | −$2.29 | $0.02 | −$2.00 | — | $4.27 |
| 2016 | — | −$3.60 | $0.07 | $1.46 | — | $1.76 |
| 2017 | $4.17 | −$1.69 | $0.04 | −$1.33 | — | $2.57 |
| 2018 | $3.58 | −$2.47 | $0.03 | −$1.71 | — | — |
| 2019 | $2.83 | −$2.36 | $0.06 | −$2.23 | — | $3.23 |
| 2020 | $2.13 | −$2.78 | $0.00 | −$0.80 | — | $1.65 |
| 2021 | $1.28 | −$1.70 | $0.00 | −$1.52 | — | $0.42 |
| 2022 | $1.60 | −$0.52 | $0.00 | −$0.40 | — | $0.03 |
| 2023 | $1.04 | −$0.28 | $0.00 | −$0.12 | — | −$0.16 |
| 2024 | $0.76 | −$0.33 | $0.00 | −$0.19 | — | −$0.22 |
| 2025 | $0.92 | −$0.02 | $0.00 | $0.26 | — | $0.12 |
Common questions about Akebia Therapeutics
How much does one share of Akebia Therapeutics earn?
Over the last 12 months, Akebia Therapeutics lost $0.11 for each share on $0.83 of sales.
Does Akebia Therapeutics pay a dividend?
Akebia Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Akebia Therapeutics’s book value per share?
Akebia Therapeutics’s book value is $0.09 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Akebia Therapeutics have?
Each share of Akebia Therapeutics has $0.57 of cash and investments and $0.18 of debt, as of June 30, 2026.
What is Akebia Therapeutics’s free cash flow per share?
$0.15 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Akebia Therapeutics bought back shares?
Akebia Therapeutics’s share count rose about 61999% from 2012 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.